Abstract: Rhabdomyosarcoma, the
R
habdomyosarcomas represent a category of soft tissue malignancies exhibiting features of skeletal muscle differentiation. Two major subtypes of rhabdomyosarcoma-alveolar rhabdomyosarcoma (ARMS) and embryonal rhabdomyosarcoma (ERMS)-have been differentiated on the basis of their histomorphologic appearance, clinical behavior, and molecular pathogenesis. The majority of rhabdomyosarcomas occur in the young, making rhabdomyosarcoma the most common soft tissue malignancy of childhood which accounts for an estimated 40% of pediatric soft tissue tumors. 1 The morphologic diagnosis of rhabdomyosarcoma is often difficult owing to its variable "small round blue cell" or "spindle cell" histomorphology. Thus, immunohistochemical detection of genes expressed during myogenic differentiation represents an important diagnostic tool. 2 In particular, the immunohistochemical detection in tumor cell nuclei of myogenin (MYOG) and MYOD1, transcription factors that function as regulators of myogenesis, currently serves as the benchmark for rhabdomyosarcoma diagnosis. 3 Although the expression of either MYOG or MYOD1 is sufficient to diagnose rhabdomyosarcoma, the sensitivity and specificity of these 2 immunohistochemical markers, even when used in combination, is imperfect. 2, 4 Negative or focal MYOG expression, particularly in ERMS, has been noted in a considerable proportion of cases. [5] [6] [7] [8] Furthermore, the interpretation and practical utility of MYOD1 immunostaining has been hindered by high background and cytoplasmic staining that renders complex the assessment of nuclear expression. 3, 6, 9 These limitations are often compounded by scant diagnostic tissue in biopsy specimens.
PAX7 is a paired box transcription factor required for the developmental specification of mammalian skeletal muscle stem cells, also known as satellite cells, a rare population of tissue-resident adult stem cells that reside at the periphery of the skeletal muscle fiber sandwiched between the basal lamina and the muscle fiber sarcolemma. 10 PAX7 is known to play a critical role in mammalian myogenesis, albeit partially redundant with its paralog PAX3. 11 In the hierarchy of transcriptional regulation of mammalian myogenesis (Fig. 1A) , PAX7 controls early lineage specification, whereas MYOD1 and MYOG regulate subsequent lineage commitment and terminal differentiation. 12, 13 Translocations involving PAX7 or PAX3 and FKHR underlie the large majority of ARMS, indicating a role for PAX7/3 in the pathogenesis of myogenic tumors. Intriguingly, recent elegant genetic studies in mice have shown that inducing oncogenic mutations in skeletal muscle progenitors, including those expressing PAX7, gives rise to rhabdomyosarcoma among other tumors. 13 Although PAX7 expression has been observed at the mRNA level in a subset of rhabdomyosarcomas, 14 its expression at the protein level and in particular its immunohistochemical evaluation as a diagnostic tool have yet to be studied. Here, we explore the diagnostic utility of immunohistochemical analyses of PAX7 expression in rhabdomyosarcoma by characterizing its expression in a series of alveolar and ERMSs, related soft tissue tumors, histologic mimics, and nonneoplastic tissues.
MATERIALS AND METHODS

Tissue Microarrays and Cases
The tissue microarrays (TMAs) were constructed using a tissue arrayer (Beecher Instruments, Silver Spring, MD) as previously described. 15 sarcoma were retrieved from the surgical pathology and consultation files of the Stanford Health Care Department of Pathology. Genetic confirmation by reverse transcription with polymerase chain reaction was previously performed for the case of CIC-DUX4 round cell sarcoma.
Histologic and Molecular Classification
Histologic classification of rhabdomyosarcomas was performed as previously described. 6 The original hematoxylin and eosin (H&E)-stained slides were reviewed by 3 pathologists. For cases without a definite histomorphologic diagnosis, the diagnosis of rhabdomyosarcoma was confirmed with immunohistochemistry for desmin, MYOG, and MYOD1. The minimum criteria for classification as rhabdomyosarcoma were: (1) immunohistochemical detection of nuclear-localized MY-OD1 or MYOG expression or (2) morphologic evidence of rhabdomyoblasts and immunohistochemical evidence of desmin expression. All cases were classified into histologic subtypes of rhabdomyosarcoma using H&E-stained slides and International Rhabdomyosarcoma Study Group/Children's Oncology Group criteria.
For correlation of translocation status with PAX7 expression in ARMS, cases of ARMS from The University of Texas MD Anderson Cancer Center, archived between 1957 and 2001, were assembled into a TMA (n = 39). All cases on this array were represented as 2 separate cores. Gene translocation status was determined by fluorescence in situ hybridization using PAX3, PAX7, and FOXO1 loci-specific probes, as previously described. 17 Only ARMS cases with molecularly defined PAX3/7-FOXO1 translocations were used for this portion of the study (n = 15).
Immunohistochemistry
After antigen retrieval, microarray sections were stained with antibodies according to standard protocols for formalin-fixed paraffin-embedded material. A monoclonal antibody against PAX7 raised in mouse was purchased from the Developmental Studies Hybridoma Bank (Iowa City, IA). 18 Anti-PAX7 antibody from hybridoma supernatant was used at a dilution of 1:200 (by volume) following antigen retrieval using citrate buffer. A monoclonal antibody against MYOG (clone F5D) raised in mouse was purchased from Dako (Carpinteria, CA). Anti-MYOG antibody was used at a dilution of 1:80 (by volume) following antigen retrieval using heat. For both PAX7 and MYOG, immunoreactivity was considered positive if >20% of tumor cells showed staining with appropriate nuclear chromogen localization. If 1% to 20% of tumor cells showed appropriate staining, the immunoreactivity was considered focal. If <1% of tumor cells showed appropriate staining, the immunoreactivity was considered negative. A monoclonal antibody against MYOD1 (clone 5.8A) raised in mouse was purchased from Leica (Buffalo Grove, IL). Anti-MYOD1 antibody was used at a dilution of 1:10 (by volume) following heat-induced antigen retrieval using the Leica Epitope Retrieval Solution 2 (EDTA-based solution at pH 9.0).
RESULTS
PAX7 expression has been used in the past as a marker of mammalian skeletal muscle stem cells, or "satellite cells." 10, 19, 20 We, therefore, first sought to validate the specificity of the immunohistochemical detection of PAX7 by analyzing its expression in skeletal muscle and other non-neoplastic tissues. Anti-PAX7 antibody showed strong, specific nuclear localization in rare cells located at the periphery of the muscle fiber (Figs. 1B and C), consistent with expression in muscle satellite cells. Constituent myonuclei of skeletal muscle fibers, in addition to other muscle-resident cell types, showed no identifiable PAX7 expression.
Having confirmed the specificity of the anti-PAX7 antibody for satellite cell nuclei in skeletal muscle, we next analyzed its expression in a broad range of nonpathologic tissue specimens (Fig. 2 ). These tissues included thyroid, tonsil, liver, skin, adrenal gland, large and small bowel, placenta, breast, prostate, seminal vesicle, cervix, peripheral nerve, salivary gland, bladder, heart, parotid gland, endometrium, hematopoietic marrow, kidney, pancreas, ovary, parathyroid, and salivary gland. Although no nuclear staining was seen in the evaluated tissues, nonspecific cytoplasmic or extracellular staining was present in thyroid, oxyntic stomach, and submandibular gland (Fig. 2) . Of note, no significant nuclear immunoreactivity was observed in tissues known to express the other diagnostically relevant paired box transcription factors PAX2 (seminal vesicle and endometrium), PAX5 (tonsil), and PAX8 (kidney, thyroid, and endometrium) (Fig. 2) . Taken together, these findings indicate that PAX7 is a specific marker of skeletal muscle progenitors in non-neoplastic human tissue.
Given that rhabdomyosarcoma is thought to represent a tumor with characteristics of skeletal muscle differentiation, we hypothesized that detection of PAX7 protein by immunohistochemistry may be diagnostically useful in the identification of rhabdomyosarcoma. We analyzed PAX7 expression in 63 cases of ERMS. Among these cases, 52 (83%) showed positive staining, 9 (14%) showed negative staining, and 2 (3%) showed focal staining (defined as nuclear immunoreactivity in 5% to 20% of lesional cells). Several PAX7-expressing ERMS cases showed negative or scant MYOG expression (Figs. 3A-D) . Although the majority of ERMS cases showed only nuclear localized PAX7 immunoreactivity, rare cases showed strong nuclear and cytoplasmic reactivity (Fig. 3B ). Cytoplasmic immunoreactivity without nuclear immunoreactivity was not observed in any cases.
We identified 16 cases of ERMS that were negative for nuclear anti-MYOG immunoreactivity (Fig. 3D) . Of these cases, 12 (75%) were positive for PAX7 expression. Among the additional 15 cases showing MYOG expression in <20% of the lesional cell population, PAX7 expression was present in all cases (15/15, 100%). There were 31 MYOG-positive cases (expression in >20% of cells), 27 of which were PAX7 positive (86%). The 2 cases of focal PAX7 expression both showed focal MYOG expression in <20% of cells. The PAX7-expressing cases of ERMS were derived from various anatomic locations, including retroperitoneal, paratesticular, orbital, vaginal, and thoracic sites. All 6 cases of botryoid ERMS showed positive PAX7 expression (6/6, 100%). In addition, the majority of examined recurrent ERMS cases (9/14, 64%) were immunoreactive for PAX7.
The finding of heterogenous PAX7 expression in ERMS cases led us to further characterize the PAX7-negative subset. There was no clear trend in histologic subtype or anatomic site among the 9 PAX7-negative tumors. Although a subset (5/9, 56%) of PAX7-negative ERMS showed MYOG expression, the remainder (4/9, 44%) was MYOG negative (Fig. 4) . Four of 9 PAX7-negative cases were recurrences (44%).
Nuclear anti-MYOD1 reactivity was present in 36.5% of ERMS cases (23/63). Interestingly, all 23 MYOD1-positive cases were also MYOG positive (23/23, 100%). Of 54 PAX7-positive ERMS cases, 22 (41%) were MYOD1 positive. A single PAX7-negative case showed MYOD1 expression (in addition to MYOG expression).
Spindle cell rhabdomyosarcoma is a histologic variant of rhabdomyosarcoma that is distinguished from other subtypes by its clinical presentation, morphologic appearance, and prognosis. 21 Earlier studies have suggested that spindle cell rhabdomyosarcomas exhibit a greater degree of myogenic differentiation relative to other variants, based on the expression of late myogenesis markers, such as titin and myoglobin. 22 We, therefore, analyzed PAX7 expression in a separate cohort of spindle cell rhabdomyosarcomas. Of 8 cases, 6 (6/8, 75%) showed nuclear anti-PAX7 immunoreactivity. These 6 PAX7-positive spindle cell rhabdomyosarcomas were also MYOG positive. The 2 PAX7-negative cases (2/8, 25%) were also MYOG negative. Therefore, although PAX7 is an early marker of myogenic differentiation in comparison with MYOG, the 2 markers showed equal sensitivity and specificity in the examined spindle cell rhabdomyosarcomas.
In contrast to the spindle cell variant, pleomorphic rhabdomyosarcoma represents a subtype with highergrade histologic features and a more aggressive clinical behavior. Previous studies have shown MYOG and MYOD1 expression in 71% and 53% of pleomorphic rhabdomyosarcomas, respectively. 23, 24 In a cohort of 7 cases of pleomorphic rhabdomyosarcoma, we identified PAX7 expression in 5 (5/7, 71%). Thus, in this set of cases, the frequency of PAX7 expression in pleomorphic rhabdomyosarcoma is similar to that of MYOG.
The evaluated ARMSs were PAX7 positive in 6 of 31 (19%) cases (Fig. 5) . Compared with ERMS, a greater proportion of ARMS cases showed negative (14/31, 45%) or focal (11/31, 36%) staining. As above, focal staining was identified as <20% of cells showing nuclear anti-PAX7 immunoreactivity (Fig. 5B) . MYOG and MYOD1 expression were additionally analyzed in a 16-case cohort of ARMS cases. As previously reported, 5,7 the large majority of ARMS cases were MYOG positive (13/16, 81%). expression was a recurrence. Among the cases of ARMS, 7 were classified histologically as the solid variant, including 2 cases negative for PAX7 expression, 2 cases showing positive PAX7 staining, and 3 cases showing focal PAX7 staining. Nuclear anti-MYOD1 immunoreactivity was identified in 4 ARMS cases (4/16, 25%). Three of 4 MYOD1-positive cases also expressed MYOG and PAX7, whereas 1 case was positive for MYOG, but not PAX7, expression.
Given the observation of PAX7 expression in a subset of ARMS cases, we hypothesized that its expression would correlate with underlying PAX3/PAX7-FOXO1 translocation. To test this possibility, we analyzed PAX7 expression in a cohort of 15 molecularly defined ARMS cases, which included 10 cases with a PAX3-FOXO1 gene fusion and 5 cases with a PAX7-FOXO1 gene fusion. Among the 15 cases, 7 (7/15, 47%) showed PAX7 expression, which was focal in 4 of 7 PAX7-positive cases. Remarkably, all 7 cases with PAX7 expression were defined by a PAX3-FOXO1 translocation, whereas none of the 5 ARMS cases with a PAX7-FOXO1 gene fusion showed PAX7 expression. Thus, PAX7 expression correlates with the presence of PAX3-FOXO1 gene fusion in ARMS.
To examine the specificity of anti-PAX7 immunoreactivity for diagnostic evaluation of rhabdomyosarcoma and other soft tissue tumors, we studied PAX7 expression in TMA samples of 697 additional nonrhabdomyosarcoma specimens, which focused on soft tissue tumors, small round blue cell tumors, and leukemia/lymphoma (Fig. 6 and Table 1 ). Among these tumors, only Ewing sarcoma showed consistent PAX7 expression (7/7, 100%). In all 7 cases of Ewing sarcoma, nuclear anti-PAX7 immunoreactivity was present in >50% of lesional cells (Fig. 6A) . Among the 690 remaining specimens, 688 (99.7%) were negative for PAX7 expression-2 of 22 examined cases (9%) of synovial sarcoma showed PAX7 expression. Of note, these synovial sarcoma cases did not have molecular confirmation of the t(X;18) translocation. Both PAX7-expressing cases of synovial sarcoma were of the monophasic spindle cell subtype.
DISCUSSION
The assessment of soft tissue sarcomas represents a diagnostically challenging area owing to morphologic overlap and incomplete molecular characterization of many of the involved entities. This is particularly true for rhabdomyosarcoma, which has a number of histologic mimics and distinguishing molecular features that can be challenging to detect. Accurate distinction between rhabdomyosarcoma and its mimics is critical as subsequent treatment and overall prognosis is based on the specific type of sarcoma. Here, we explore the molecular diagnostics of rhabdomyosarcoma with a particular focus on the expression of PAX7 in alveolar and embryonal subtypes, non-neoplastic tissues, and histologically similar soft tissue or small round blue cell tumors.
In our studies, PAX7 showed particular utility in the evaluation of ERMS, where we found that PAX7 expression was present in 86% of cases. This finding is of particular significance in the diagnosis of ERMS because, although MYOG is a relatively specific marker of rhab- domyosarcoma, a number of prior studies have noted that MYOG expression is frequently negative or scant in cases of ERMS. Hostein et al 7 found that 37 of 64 ERMS cases (58%) showed MYOG expression in <50% of tumor cells. Twenty-two cases (34%) showed MYOG expression in <29% of cells. Dias et al 5 likewise found that 15 of 17 ERMS cases (88%) showed MYOG expression in <50% of tumor cells with 59% of cases (10/17) showing MYOG expression in <10% of cells. We find a similar frequency of ERMS cases with limited MYOG expression in the present study, with 31 of 63 cases (49%) being MYOG-negative or MYOG-focal (expression in <20% of tumor cells). Importantly, 75% of MYOG-negative cases and 100% of MYOG-focal cases showed PAX7 expression in >20% of cells. In contrast, only 5 of 63 ERMS cases (8%) showed MYOG staining in the absence of PAX7 staining. These findings highlight the potential diagnostic value of PAX7 immunohistochemistry in the evaluation of rhabdomyosarcoma, especially those of the embryonal subtype.
Of particular interest, we observe that, among a large and diverse array of neoplasms, PAX7 expression is limited to rhabdomyosarcoma and Ewing sarcoma. This finding corroborates similar observations of PAX7 expression in 3 cases of Ewing sarcoma in a prior study, 25 which did not examine PAX7 expression in rhabdomyosarcoma itself. On the basis of these findings, we conclude that Ewing sarcoma should be considered in the differential diagnosis of a PAX7-expressing small round blue cell neoplasm. Helpful clues to differentiating rhabdomyosarcoma and Ewing sarcoma include immunohistochemical analysis of desmin expression, which is seen in 83% of rhabdomyosarcomas, 26 but only 2% of Ewing sarcomas, 27 and molecular genetic evidence of Ewing sarcoma-related translocations. Biologically, the identification of PAX7 expression in the majority of studied Ewing sarcoma cases is consistent with the molecular features of primitive mesoderm characteristic of this entity and accounts for the observed myogenic differentiation seen in rare cases. 23, 24, 27, 28 Future studies aimed at inducing the terminal Taken together, the studies presented herein suggest several opportunities for-and limitations of-implementation of analyses of PAX7 expression in clinical practice. Currently, the standard for demonstrating skeletal muscle differentiation in rhabdomyosarcomas is identification of nuclear immunoreactivity of anti-MYOG or anti-MYOD1 antibodies. In our studies, PAX7 expression, in comparison with analysis of either MYOD1 or MYOG, was a more sensitive marker of skeletal muscle differentiation in ERMSs: the sensitivity of PAX7, MYOG, and MYOD1 expression in ERMS was 86% (54/63), 75% (47/63), and 36.5% (23/63), respectively. Among ARMS cases, MYOG was a more sensitive marker, with the sensitivity of PAX7, MYOG, and MYOD1 expression being 63% (10/16), 81% (13/16), and 25% (4/16), respectively. It is important to note, however, that there were several cases of both ERMS and ARMS that showed expression of only one of either PAX7 or MYOG. Notably, we found that PAX7 is not entirely specific for rhabdomyosarcoma, as it is expressed in all 7 analyzed cases of Ewing sarcoma. Excluding cases of Ewing sarcoma, PAX7 expression was seen in only 0.3% of nonrhabdomyosarcomas. Although MYOD1 and MYOG are regarded as quite specific markers of myogenic differentiation, prior studies have noted nuclear immunoreactivity for these antibodies in rare nonrhabdomyosarcoma cases. In 1 such study, 9 7 of 107 nonrhabdomyosarcomas (6.5%) showed MYOG expression, whereas "cytoplasmic and nonspecific background staining and reactivity of nonmyoid tissues" by anti-MYOD1 antibody "hindered its practical utility in paraffin-embedded samples," indicating that, like PAX7, there are caveats to the interpretation of positive MYOD1/MYOG immunostaining alone as evidence of skeletal muscle differentiation.
One can, therefore, imagine multiple approaches to the utilization of PAX7 analyses in the immunohistochemical evaluation of candidate rhabdomyosarcomas. There is no certain advantage to using PAX7 expression in lieu of MYOG expression in a primary screen for skeletal muscle differentiation. Although PAX7 was a somewhat more sensitive marker in ERMS, MYOG was somewhat more sensitive in ARMS. If PAX7 analyses are used as a primary screening marker, lack of expression would require additional studies with MYOG or MYOD1 to completely rule-out skeletal muscle differentiation, given that PAX7 does not identify all tumors showing myogenic gene expression. In this scenario, identification of PAX7 expression would be diagnostic of a rhabdomyosarcoma, unless a small round blue cell morphology was identified, in which case additional immunohistochemical or molecular studies would be required to exclude a Ewing sarcoma, as discussed above. Alternatively, PAX7 studies may be used secondarily in cases showing desmin expression, but a lack of MYOG or MYOD1 expression in an initial screening assessment, to account for the MYOG/MYOD1-negative or MYOG/ MYOD1-focal rhabdomyosarcomas identified in this study. In another scenario, the practicing pathologist may find utility for PAX7 expression analyses in evaluating a small round blue cell tumor concerning for Ewing sarcoma. In this setting, our studies suggest that identification of a PAX7-positive, desmin-negative tumor would suggest the diagnosis of Ewing sarcoma and would warrant follow-up molecular analyses for Ewing-related translocations.
PAX7 is one of 9 members of the paired box (Pax) family of genes, each of which has a unique function and pattern of expression. PAX2, PAX5, and PAX8 are Pax gene lineage markers that are routinely assessed in current clinical practice. Intriguingly, recent work has shown that an antibody against PAX5, a marker of the B-cell lineage, shows immunoreactivity toward a subset of ARMS, but not ERMS. 29 Indeed, this finding can be a diagnostic pitfall in morphologically challenging cases of ARMS. 30 Because anti-PAX5 immunoreactivity correlated with the presence of PAX3/PAX7 translocations in a small subset of studied cases, the anti-PAX5 immunoreactivity seen in ARMS was attributed to cross-reactivity with PAX3/ PAX7. 29 These studies did not correlate anti-PAX5 immunoreactivity with specific translocations (ie, PAX3 vs. PAX7). In the present study, we observe that a majority of ERMS cases show robust PAX7 expression, whereas PAX7 expression is relatively limited in ARMS. Given that Sullivan and colleagues see PAX5 immunoreactivity primarily in ARMS, our findings suggest that the observed PAX5 cross-reactivity is most likely attributable to recognition of PAX3 and not PAX7. In addition, we find no evidence of significant immunoreactivity of the anti-PAX7 antibody with non-neoplastic cells other than the expected localization within skeletal muscle satellite cells. This finding suggests that there is limited cross-reactivity of anti-PAX7 antibody for nonmyogenic Pax genes.
PAX7 has been used extensively in the past in basic science studies as a genetic marker of the adult mouse skeletal muscle satellite cell population. Indeed, recent studies in which the entire population of PAX7-expressing cells was conditionally ablated from adult mice showed that PAX7-expressing satellite cells are responsible for the robust skeletal muscle regenerative capacity seen in adult animals. 31 Subsequent studies showed that the level of PAX7 expression correlates with "stem cell" attributes in satellite cells. 20 These findings raise the hypothesis that PAX7 expression also identifies cells with tumorigenic stem cell properties in human rhabdomyosarcoma. The heterogeneity of PAX7 expression observed in our studies suggests that rhabdomyosarcomas vary considerably in terms of the frequency of PAX7-expressing cells, mirroring the clinical variability of tumor recurrence and patient survival in rhabdomyosarcoma. If PAX7 expression correlates with a cancer stem cell phenotype, evaluation of PAX7 may have prognostic significance in rhabdomyosarcoma. Additional studies designed to correlate features of PAX7 expression with clinical behavior of rhabdomyosarcoma samples will be critical in evaluating this possibility.
Fusion of PAX3/7 with FOXO1 represents a molecular lesion associated with the majority of cases of ARMS. Our observation of PAX7 expression in a subset of ARMS cases raised the intriguing question of whether PAX7 expression in ARMS relates to the underlying genetic translocation. Interestingly, in a set of molecularly defined ARMS cases, we find that, although PAX7 expression is seen in 70% of cases (7/10) bearing the PAX3-FOXO1 translocation, no cases bearing the PAX7-FOXO1 translocation express PAX7. What accounts for this surprising correlation? The anti-PAX7 antibody used in this study was originally raised against an immunogen consisting of amino acids 352-523 of chicken Pax7. 18 This immunogen represents a distal segment of PAX7, including the C-terminus. Therefore, although the antibody's epitope has not been mapped, it falls within this distal region against which the antibody was raised. Conversely, the segment of human PAX7 that is involved in the PAX7- FOXO1 translocation consists of an N-terminal region (amino acids 1 to 383) that has little overlap with the immunogen sequence: the portion of PAX7 bearing the epitope targeted by the antibody used in this study includes only approximately 30 amino acids retained in the fusion protein. 24 Although a second, intact PAX7 allele encoding a version of PAX7 including the antibody-targeted epitope is retained, previous elegant studies have shown significantly reduced expression of the intact PAX7 allele relative to the translocation allele in PAX7-FOXO1 ARMS. With this information in mind, our observation of limited PAX7 expression in ARMS cases bearing the PAX7-FOXO1 translocation can be accounted for by loss of expression of the antibody epitope in the fusion protein and decreased or loss of expression of the normal PAX7 allele.
In summary, PAX7 expression is a useful marker of skeletal muscle differentiation in rhabdomyosarcoma, particularly of the embryonal subtype, with specificity for rhabdomyosarcoma and Ewing sarcoma. PAX7 may be especially helpful in cases of ERMS in which MYOG immunoreactivity is limited or undetectable. Additional molecular or immunohistochemical studies are warranted if PAX7 expression is seen in a case for which Ewing sarcoma is on the clinical or histopathologic differential diagnosis. The development of new antibodies and techniques for analysis of gene expression are likely to enhance our capacity for diagnostic assessment of myogenic differentiation in human cancers. Future studies of PAX7 expression in rhabdomyosarcoma will enhance our understanding of its significance as a prognostic marker or surrogate marker of underlying molecular lesions.
